Ikarian Capital’s Janux Therapeutics JANX Stock Holding History

Ikarian Capital’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-365,200	Closed	-$16.6M	–	191
2024 Q3	$16.6M	Buy	+365,200	New	+$15.9M	2.31%	7

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Ikarian Capital's JANX Position: Q4 2025 in Review

Ikarian Capital sold out of Janux Therapeutics (JANX) in Q4 2025, closing a stake of 54,691 shares — an estimated $1.34M sold.

Ikarian Capital first reported a position in JANX in Q4 2024 and held it in 4 quarters. The position peaked at $4M in Q4 2024. 176 funds tracked by Wall St. Rank hold JANX as of Q4 2025.

Ikarian Capital reported no remaining Janux Therapeutics position as of Q4 2025 after selling out during the quarter.
Ikarian Capital sold 54,691 Janux Therapeutics shares in Q4 2025, an estimated $1.34M.
Ikarian Capital first reported a position in Janux Therapeutics in Q4 2024 and held it in 4 quarters.
Ikarian Capital's Janux Therapeutics position peaked at $4M in Q4 2024.
176 funds tracked by Wall St. Rank held Janux Therapeutics as of Q4 2025.

Based on Ikarian Capital's 13F filing for Q4 2025, filed 18 Feb 2026.